Insilico Medicine has dosed the first patient in a Phase III clinical trial for Rentosertib, an AI-discovered drug targeting idiopathic pulmonary fibrosis (IPF). The trial, conducted at multiple centers in China, aims to evaluate the drug's efficacy and safety over 52 weeks in 320 patients. Rentosertib inhibits TNIK, a novel target linked to fibrosis, and showed promising Phase IIa results including improved lung function. Insilico expects the trial to take 3-4 years to complete and aims for regulatory approval to offer a new treatment option for IPF, a serious lung disease with limited therapies. The company also reported strong financial growth in 2026, driven by partnerships and AI-driven drug discovery advancements.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
Bitcoin experienced a 5.7% price drop from $82,300 to $77,620 over five days but has started to rebound, rising 2.4% from its recent low. Despite long-term holders selling and taking profits, Bitcoin's price remains strong above the $76,000 demand zo...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
At the Barclays 19th Annual Global Consumer Staples Conference, Dine Brands executives discussed their portfolio, which includes 1,550 Applebee's units, 1,800 IHOP units, and 100 Fuzzy's Taco units. The company emphasized the strong consumer appeal o...
Shopify has acquired Tailwind Labs, known for its popular Tailwind CSS framework used by major platforms like ChatGPT and Reddit. The Tailwind team will now focus on helping Shopify merchants design custom storefronts, manage sales and inventory, and...
